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ABSTRACT 
 
Aims: The International Collaboration on Cancer Reporting (ICCR) has provided detailed datasets 
based upon the published reporting protocols of the Royal College of Pathologists, The Royal College 
of Pathologists of Australasia and the College of American Pathologists. Methods and results: The 
dataset for carcinomas of renal tubular origin treated by nephrectomy was developed to provide a 
minimum structured reporting template suitable for international use and incorporated 
recommendations from the 2012 Vancouver Consensus Conference of the International Society of 
Urological Pathology and the fourth edition of the World Health Organization Bluebook on tumours 
of the urinary and male genital systems published in 2016. Reporting elements were divided into 
those, which are Required and Recommended components of the report. Required elements are; 
specimen laterality, operative procedure, attached structures, tumour focality, tumour dimension, 
tumour type, WHO/ISUP grade, sarcomatoid/rhabdoid morphology, tumour necrosis, extent of 
invasion, lymph node status, surgical margin status, AJCC TNM staging and co-existing pathology. 
Recommended reporting elements are; pre-operative treatment, details of tissue removed for 
experimental purposes prior to submission, site of tumour(s) block identification key, extent of 
sarcomatoid and/or rhabdoid component, extent of necrosis, presence of tumour in renal vein wall, 
lymphovascular invasion and lymph node status (size of largest focus and extranodal extension).  
Conclusions: It is anticipated that the implementation of this dataset in routine clinical practise will 
inform patient treatment as well as provide standardized information relating to outcome prediction. 
The harmonisation of data reporting should also facilitate international research collaborations. 
 
Key words: renal cell carcinoma, nephrectomy, datasets, tumour, grading, staging. 
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Introduction  
 
Several studies have demonstrated that a structured approach to pathology reporting improves the 
completeness and quality of reports by ensuring that all essential information necessary for diagnosis 
and prognostic assessment is included.1-4 The use of a structured format has also been shown to be 
superior to that of a narrative report with regard to readability and to access of information. In 
particular all the essential factors are presented in a list or table with headers and responses, rather 
than being buried in long narrative text.5 
 
As a result of these studies, the development of structured reporting checklists has been advocated 
internationally over the past two decades and in particular pathologists from Australia,6 the United 
Kingdom7 and the United States of America8, have, for some years, produced standardised cancer 
reporting protocols for national implementation.  While each of the protocols for specific organs are 
similar in nature, having an evidence-based approach, each jurisdiction has developed their cancer 
checklists in a different manner, employing differing terminology. This means that in some instances 
descriptions of similar elements may vary in meaning, impeding the possibility of international 
collaborative research and benchmarking studies.  
 
With the ever-rising complexity of cancer diagnosis and treatment, the availability of standardised 
evidence-based checklists for each type of cancer is of increasing value to pathologists worldwide.  
Given this, a consortium of pathology colleges, societies and major cancer organisations agreed to 
collaborate on the production of standardised reporting checklists and piloted the development of four 
internationally standardised cancer reporting protocols in 2011. The initial pilot project to develop 
four cancer datasets – Melanoma, Endometrium, Prostate (Radical Prostatectomy specimen) and Lung 
– provided an opportunity to trial a number of development methodologies.  From this the current 
framework for the development of datasets emerged and is published in Guidelines for the 
Development of ICCR Cancer Datasets.9 Based upon the success of this project the International 
Collaboration on Cancer Reporting (ICCR) was formed with the goal of producing  unified, 
internationally validated and evidence-based pathology datasets for cancer reporting, for use 
internationally.   
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This process of compiling datasets by the ICCR is based on the development of a single cancer dataset 
with the aid of a Dataset Authoring Committee (DAC).  Of primary importance to the DAC is the 
selection of a chair by the Dataset Steering Committee (DSC) to oversee the development process. 
Once appointed, the chair assists the DSC to identify members of the DAC.  The DSC, in convening a 
DAC for a specific cancer seeks members covering a wide geographic and linguistic diversity, as well 
as having a high level of expertise in the specific cancer.   
 
The current review presents the recommendations of the DAC in relation to the development of a 
structured reporting protocol for kidney specimens containing renal cell neoplasia, obtained through 
either partial or total nephrectomy, usually undertaken with a curative intent. The protocol 
incorporates the recommendations of the International Society of Urological Pathology (ISUP) 
Vancouver Conference on Renal Neoplasia,10 the 2016 World Health Organization (WHO) 
Classification of Renal Tumours11 and the eighth edition of the American Joint Committee on Cancer 
TNM Staging Classification of 2017.12  It is anticipated that the recommended elements will provide 
contemporary guidance for the reporting of renal malignancies and that reports which adhere to these 
guidelines will contain sufficient data to inform both patient treatment and outcome prediction. 
  
Methods 
 
The DAC convened for the construction of the renal cancer dataset consisted of 14 members. Twelve 
of these were urological pathologists with special expertise in renal cancer, one of the members was a 
urologist while the final member was the ICCR Project Manager who assisted in all aspects of the 
development process. An ICCR representative was also appointed to the committee with the role of 
providing guidance and support to the Chair of the DAC regarding ICCR standards. In addition to an 
authoring function, the ICCR representative had a quality assurance role within the committee, to 
ensure adherence to ICCR guidelines relating to evidence-based recommendations. For the renal cell 
carcinoma (RCC) protocol, the ICCR representative also co-chaired the development process.  
 
The renal cancer reporting protocol was initially drafted by the Chairs of the DAC and the ICCR 
Project Manager, following a detailed review of published datasets/protocols and relevant articles.  
Importantly Required and Recommended elements of the reporting protocols were identified. 
Required elements are those for which there was unanimous agreement by the committee that the 
element was essential for histological diagnosis, clinical management, staging and/or assessment of 
prognosis. Required elements are mandatory elements of a pathology report and the sum of these is 
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the minimum information which should be included in the report. Evidentiary support at Level III-2 
or above, based on prognostic factors in the National Health and Medical Research Council 
(NHMRC) levels of evidence document and defined as “Analysis of prognostic factors amongst 
persons in a single arm of a randomised controlled trial”,13 was required to support Required 
(mandatory) elements. Rarely, where Level III-2 evidence was not available, an element was 
categorised as Required with unanimous agreement of the expert panel. Recommended elements are 
those which were considered non-mandatory but defined as being clinically important and 
recommended as appropriate for good practice. It was agreed that Recommended elements should 
ideally be included in a pathology report although they have not yet been validated by evidence, or are 
not regularly utilized in patient management.  Commentary, by way of explanatory text, diagrams or 
tables was included in the draft dataset, and was added to clarify the elements and to further define the 
manner in which an item should be reported in order to; foster reproducibility, provide an explanation 
why an element is included in the dataset by specifying how the item will assist with clinical 
management of the specific cancer, cite published evidence in support of the inclusion of the element, 
and to clarify any exceptions or issues that may be encountered by the reporting pathologist.  
 
The draft dataset was formatted into a ‘voting’ document and circulated to the DAC for feedback.  
This feedback was then compiled and provided back to the DAC prior to a series of web 
meetings/teleconferences to discuss the elements.   
 
Once agreed by the DAC, the dataset was posted to the ICCR website for an 8 week period of public 
consultation.   Following the open consultation phase, feedback was reviewed and relevant changes 
drafted. At this stage a decision was made by the ICCR to incorporate the eighth edition TNM staging 
system and dataset publication was delayed until this could be included. Following publication of the 
eighth edition TNM by the AJCC, the dataset was revised and updated, reviewed by the DAC and 
changes finalised and ratified by the DSC. 
 
Results 
 
This dataset was developed for the reporting of renal excision specimens where the operation was 
undertaken for the treatment of carcinomas of renal tubular origin.  If there is more than one tumour in 
a kidney or if tumours are bilateral, then multiple datasets should be used. The dataset is not intended 
for tumours that are not of renal tubule origin, including urothelial carcinoma arising from the upper 
renal tract, Wilms tumour and other nephroblastic and mesenchymal tumours.  
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Required dataset elements  
The Required elements in the dataset are listed in Table 1.  
 
Specimen laterality 
Information regarding the laterality of the specimen  is a requirement for patient/specimen 
identification purposes and furthermore assists the pathologist in orienting the specimen prior 
to gross dissection. 
 
Operative procedure 
The nature of the surgical procedure should be recorded for medico-legal purposes and to assist the 
identification of both the patient and specimen.  Three surgical techniques are routinely employed;  
 A radical nephrectomy specimen is defined as a resection of Gerota’s fascia and its 
entire contents including the kidney, perinephric fat and lymphatics, as well as a 
length of ureter. The specimen may or may not include the ipsilateral adrenal gland.  
 A simple nephrectomy results in the removal of a kidney including a small length of 
ureter.  
 A partial nephrectomy specimen varies from local resection of the tumour with a thin 
rhind of apparently normal renal tissue, to a segment of a tumour-bearing kidney 
containing variable portions of the calyceal or renal pelvic collecting system. 
The nature of the surgical procedure is also of importance when determining the assessment of 
surgical margins.  While all surgical margins should be evaluated, it is especially important for partial 
nephrectomy specimens that the intra-renal surgical margin be carefully evaluated, so as to ensure that 
no residual tumour is present in the remaining renal tissue.  
 
Accompanying/attached structures 
Occasionally tissues, other than the usual structures removed during the nephrectomy procedure, are 
received as part of the operative specimen.  These may include contiguous structures infiltrated by 
tumour or affected by concomitant inflammation/infection. These may also include tissues containing 
local or distant metastases. These tissues should be recorded for patient/specimen identification 
purposes, while their subsequent histological assessment will inform tumour staging. 
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Tumour focality 
Although clear cell RCCs are usually solitary, other morphotypes of renal cell neoplasia, especially 
papillary RCCs and carcinomas arising in the setting of acquired cystic/ end-stage renal disease, are 
more commonly multifocal. The presence of multiple tumours in a nephrectomy specimen may be the 
only indication that the tumours may be part of a hereditary syndrome associated with the 
development of RCC, in particular von Hippel Lindau, Birt-Hogg-Dubé and hereditary papillary 
carcinoma syndromes. If multiple carcinomas are present it is important that this be recorded and a 
separate protocol used for each tumour.  In particular it is important to record the diagnostic and 
prognostic parameters associated with the most significant tumours (largest, highest pT-category, 
highest grade). The histological subtype of the tumours may be similar or different, and occasionally 
diverse morphotypes may be present in the same kidney. When numerous carcinomas are present the 
recommendation is that the details of the 5 largest tumours should be recorded.14 
 
Maximum tumour dimension 
Measurement of tumour size is necessary for staging purposes as this is the defining feature of the 
pT1 and pT2 staging categories of the AJCC TNM staging classification.12 Further it has been shown 
that for clear cell RCC tumour size correlates with outcome as a continuous variable and also predicts 
renal sinus invasion.15,16  
 
Measurement of tumour size should be undertaken following detailed dissection of the gross specimen 
and the greatest dimension should be recorded. Tumour extending into extracapsular tissue and/or the 
renal sinus, in continuity with the primary intra-renal tumour should be included in the measurement, 
while tumour within the renal vein and beyond should not be included. If multiple tumours are 
present, the greatest dimension of the five largest tumours should be recorded.14 
 
 
Histological tumour type   
Many of the various morphotypes of renal epithelial neoplasia exhibit varying clinical behaviour and 
prognosis.11,12,17-22 This has been confirmed in large single and multicentre studies for the main 
tumour sub-types. Several series have also clearly demonstrated that many of the newly described 
entities of renal malignancy have a prognosis that differs from that of clear cell RCC.22  In addition to 
this, protocols for the various  adjuvant therapies relate to specific tumour morphotypes. 23   
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Currently recognized morphotypes of RCC are shown in Table 2.  Papillary RCC has traditionally 
been subdivided into Type 1 and Type 2.24 Recent studies have shown these tumours to be clinically 
and biologically distinct. Type 1 tumours are associated with alterations in the MET pathway while 
type 2 tumours are associated with activation of the NRF2-ARE pathway. On the basis of molecular 
features type 2 tumours may be sub-divided into at least 3 subtypes.25 Type 1 and type 2 tumours 
show differing immunohistochemical staining, with type 1 tumours more frequently expressing 
cytokeratin 7 in comparison to type 2.10,11,24,25  Oncocytic papillary RCC is an entity included in the 
fourth edition of the WHO renal tumour classification.11 While not fully characterized, it is 
recommended that this tumour be included in the broader papillary RCC category as a specific 
subtype.  
 
The 2012 ISUP Vancouver Classification of  Renal Tumours defined a novel classification category 
for newly described RCC. These were designated emerging/provisional morphotypes.10 While 
appearing distinctive, these rare tumours had not been fully characterized by morphologic, 
immunohistochemical and molecular studies at the time of publication of the Classification. This 
category was also included in the fourth edition of the WHO classification of renal neoplasia. In the 
WHO classification oncocytoid RCC post-neuroblastoma, thyroid-like follicular RCC, anaplastic 
lymphoma kinase (ALK) rearrangement-associated RCC and RCC with (angio) leiomyomatous 
stroma were included in this category. These entities, as well as more recently reported emerging 
RCC morphotypes (multiple oncocytoma-like tumours associated with oncocytosis, biphasic alveolar 
squamoid RCC and eosinophilic solid and cystic RCC)26-28 should be classified under ‘other’ with the 
name of the tumour specified.  
 
The prognosis of RCC varies according to morphotype. Papillary RCC is associated with a more 
favourable outcome than clear cell RCC. A more favourable outcome has also been reported for 
multilocular cystic renal neoplasm of low malignant potential, mucinous tubular and spindle RCC, 
clear cell papillary RCC and tubulocystic RCC, while collecting duct carcinoma, acquired cystic 
disease of kidney-associated RCC and hereditary leiomyomatosis-associated RCC have a less 
favourable prognosis.11,22 Papillary subtyping is also of prognostic significance with type 1 tumours 
having a better prognosis than those with type 2 morphology.22,24,25 
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Histological grade of tumour 
The WHO/ISUP grading system for RCC is shown in Table 3. This grading system was adopted by 
the 2012 Vancouver Consensus Conference on Renal Neoplasia and was endorsed by the WHO, being  
included in the fourth edition of the Bluebook Classification of Renal Tumours.11,22 This  system has 
been validated as a prognostic parameter for clear cell and papillary RCC.22,29-31 The current 
recommendation is that chromophobe RCC is not graded.11,32 While the grading system has not been 
validated for other tumour types it may be used for descriptive purposes with an added note that the 
grading should not be taken as a prognostic indicator.33 Grade should be based upon the single high 
power field showing the highest grade. 
 
Sarcomatoid morphology 
The presence of Sarcomatoid morphology in RCC represents epithelial-mesenchymal transformation 
and is seen in approximately 5% of RCCs. This morphology represents a de-differentiation end point 
for RCC and is associated with a poor prognosis.
22,34-37  
Numerous studies have confirmed that 
sarcomatoid morphology may occur within any of the recognized morphotypes of RCC and is a 
feature of high grade disease, with an associated poor prognosis.10,11 The five year survival for 
patients with sarcomatoid morphology ranges from 15 to 22% and is stage dependent.10,11,22,34-38 While 
the presence of sarcomatoid morphology should be reported separately, it is also a defining feature of 
WHO/ISUP grade 4 tumours.22 
 
Rhabdoid morphology 
Similar to sarcomatoid morphology, rhabdoid morphology in RCC is a feature of high grade 
disease.22,39 Tumours showing this phenotype resemble rhabdoid cells having bulky eosinophilic 
cytoplasm and an eccentric nucleus, often with a prominent nucleolus.10,11 Several studies have 
confirmed that rhabdoid morphology is associated with a poor prognosis, with 71% of patients with 
developing metastases over a mean follow-up of 4.5 months. In a separate study it was noted that 43% 
of patients had died within 2 years, with survivals ranging from 8-31months.22,39-41 In approximately 
25% of tumours with rhabdoid morphology, there is co-existing sarcomatoid carcinoma.11 In addition 
to the separate reporting of rhabdoid morphology in RCC, this is also incorporated into the 
WHO/ISUP grading system as a feature of Grade 4 tumours.22 
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Necrosis 
The presence of tumour necrosis has been shown to be a prognostic indicator for clear cell and 
chromophobe RCC independent of tumour stage.22,42 Papillary RCC typically contains foci of 
necrosis, however the prognostic significance of this is, at best, debated. At present it is recommended 
that the presence of both macroscopic and microscopic (coagulative) necrosis be recorded.22 Where 
previous renal biopsy has been undertaken, this may result in  biopsy-related necrosis which may not 
have the same prognostic association.  For patients who have undergone pre-surgical renal 
embolization, the degree of tumour-related necrosis cannot be assessed. 
 
Extent of tumour invasion 
Most macroscopic and microscopic features relating to the extent of invasion by tumour are required 
dataset elements although the presence of tumour in the wall of the renal vein is a recommended 
element (Tables 1 and 4).  
The extent of tumour invasion must be recorded as “tumour limited to the kidney” or recorded for 
each of the following: 
 Tumour spread beyond the renal capsule 
 Tumour in renal sinus 
 Tumour extends beyond Gerota’s fascia 
 Tumour in major veins (renal vein or its segmental branches, inferior vena cava) 
 Tumour in pelvicalyceal system  
 Tumour in adrenal gland 
 Tumour in other organs/structures 
Extra-renal extension of tumour is a feature of pT3 and pT4 staging categories of the TNM 
staging classification (Table 5). The determination of extrarenal extension of tumour into 
peri-renal fat requires histological evidence of tumour beyond the renal capsule. 
 
The renal sinus is the compartment that lies between the renal parenchyma and the renal pelvis and 
calyces. This compartment contains varying amounts of fat and is rich in lymphatics. As a 
consequence infiltration of the renal sinus is the principal route for the extension of tumour beyond 
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the kidney.41 The identification of tumour directly infiltrating the renal sinus or large vessels has 
prognostic significance and this information is required for staging purposes.12,43 Infiltration of the 
renal sinus is often an under-recognized phenomenon.
44
 In view of this the renal sinus fat should be 
carefully assessed and generously sampled in order to detect renal sinus fat involvement. If renal sinus 
invasion is seen on gross inspection of the specimen, then only one confirmatory section need be 
taken. If there is no evidence of renal sinus invasion grossly, then sampling should consist of at least 
three blocks of tissue.14 Histologically renal sinus invasion is confirmed when there is tumour in 
contact with renal sinus fat, within the loose connective tissue clearly beyond the renal parenchyma of 
the renal sinus or in endothelial-lined spaces (with or without mural smooth muscle) within the renal 
sinus (Fig. 1).41 It is likely that renal sinus invasion is preceded by involvement of renal sinus veins. 
Renal sinus invasion is most commonly seen in clear cell RCC and for this RCC morphotype appears 
to be associated with tumour size. In particular it has been noted that in clear cell RCC s ≥ 7cm in 
diameter, renal sinus invasion was seen in > 90% of cases.16,45  For this reason the AJCC recommend 
that in tumours >7cm diameter renal sinus invasion should be suspected and sampling should be 
appropriately targeted.12 
 
Involvement of the renal sinus by tumour is a feature of pT3a tumour staging category of the TNM 
classification (Fig. 2). It has also been shown that involvement of lymphatics within the renal sinus is 
of prognostic significance.46 There is evolving literature suggesting that renal sinus fat involvement 
predicts a more aggressive outcome than peripheral perinephric fat invasion.16,45  
 
Careful gross examination of the specimen to assess large vessel invasion for example of the renal 
vein or beyond (if applicable) should be undertaken and any observation should be confirmed by 
histological evaluation. 
 
Macroscopic infiltration rather than microscopic evidence of invasion of the renal vein was a feature 
of pT3a in earlier editions of the TNM classification, however, it has been shown that microvascular 
invasion correlates with outcome independent of T category, grade and perirenal fat invasion.47 
Further, it is appreciated that infiltration of the renal vein may be overlooked on gross examination. 
For this reason the qualifier “grossly”, in relation to renal vein invasion, was removed as part of the 
definition of the pT3a staging category in the eighth edition of the AJCC staging system. Extension of 
tumour beyond Gerota’s fascia is a feature of the pT4 staging category of the TNM staging system. 
(Fig. 3).12  
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When renal carcinoma involves the adrenal gland, it is important to document whether the 
involvement is contiguous spread of tumour or a separate (non-contiguous) nodule of carcinoma.12 It 
is now recognized that direct spread of tumour to the ipsilateral adrenal gland has an outcome similar 
to pT4 tumour (Fig. 4).48,49 In earlier TNM classifications this was included in the pT3a category, 
however, in view of these recent findings this was included as a feature of the pT4 category in the 
seventh edition of the UICC TNM classification. In contrast a discrete, separate nodule in the adrenal 
gland is considered M1 disease.12  
 
The presence of metastatic disease at any site (excepting lymph nodes) is the defining feature of the 
pM1 staging category of the TNM staging classification.12 
 
Lymph node status  
In earlier editions of the UICC/AJCC TNM classifications, the number of lymph nodes infiltrated by 
tumour was used to differentiate pN categories. This classification has been now been simplified and 
the requirement is that the presence or absence of lymph node involvement by tumour must be 
recorded.11  
 
Margin status    
Assessment of surgical margins is important in determining if residual tumour is present either in the 
residual kidney, for partial nephrectomy specimens or in the renal bed for nephrectomy specimens. 
For a partial nephrectomy specimen, the renal parenchymal margin should be inked and sampled 
widely for histological assessment. Most partial nephrectomy specimens also contain a portion of 
perinephric fat overlying the tumour site and this margin should also be assessed. In situations where 
no perirenal fat is submitted, the renal capsular margin should be inked and examined histologically. 
In nephrectomy specimens the ureteric, major vascular (renal vein, renal artery) and soft tissue (peri-
renal fat and Gerota’s fascia for radical nephrectomy specimens), including renal sinus margins, 
should be examined and documented in the report. There was consensus in the ISUP Vancouver 
Consensus Conference that a renal vein margin should be considered positive only if there was 
adherent tumour at the margin and that this had been confirmed microscopically.14  
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Co-existing pathology in non-neoplastic kidney 
It is important to recognize that renal neoplasia may co-exist with non-neoplastic renal disease and 
that this may be evident in nephrectomy and nephroureterectomy specimens.50,51 
Arterionephrosclerosis (or hypertensive nephropathy) is identified in up to 30% of cases while other 
renal diseases that may more commonly be encountered are diabetic nephropathy thrombotic 
microangiopathy, focal segmental glomerulosclerosis, and IgA nephropathy. If there is > 20% global 
glomerulosclerosis or advanced diffuse diabetic glomerulosclerosis then this is predictive of 
significant decline in renal function 6 months following radical nephrectomy.51 Detailed evaluation 
for the presence of non-neoplastic renal disease should be performed in each case and if necessary 
PAS and/or Jones methenamine silver stained sections should be obtained. Where appropriate, 
consultation with a nephropathologist should be requested. 
 
Pathological staging summary 
This dataset is based upon the definitions and recommendations of the eighth edition of the American 
Joint Committee on Cancer TNM staging classification published in 201712 (Table 5). This was 
implemented internationally in January 2018.  
 
Recommended dataset elements  
Those elements which are not a required component of a pathology report, but which provide 
important information that relates to diagnosis, treatment and/or prognostic assessment, are classified 
as recommended elements and are listed in Table 4. 
 
Pre-operative treatment 
Pre-operative treatments may significantly alter the gross and microscopic appearance of the tumour. 
 
Tissue removed from specimen prior to submission 
In some laboratories tissues are removed for biobanking and research purposes. It must be noted that 
pathologic evaluation of any surgical specimen requires a detailed examination of the complete 
specimen. If tissue has been removed prior to examination this could compromise diagnosis, staging 
and prognostic assessment. As a consequence it is recommended that experimental tissues be removed 
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by the reporting pathologist or if this is not possible, that the site of sampling be carefully documented 
to ensure that reporting is not compromised. 
 
Tumour site(s)  
Documentation of the position of the tumour in relation to the boundaries of the kidney and the 
surgical resection margin is important for staging purposes, for both radical nephrectomy and partial 
nephrectomy specimens. The position of the tumour in relation to the renal cortex or medulla may 
also have diagnostic importance. This is especially important for small tumours where a site of origin 
within the medulla would support a diagnosis of collecting duct carcinoma or medullary carcinoma.11 
For partial nephrectomy specimens it is recommended that the distance from the tumour to the closest 
surgical margin should be measured. 
 
Block identification key  
The site of sampling of all tissue blocks removed from the surgical specimen should be recorded.  
This information should be documented in the final pathology report and is particularly important 
should the need for internal or external review arise. In such instances the reviewer needs to be clear 
as to the origin of each block in order to provide an informed specialist opinion. If this information is 
not included in the final pathology report, it should be available on the laboratory computer system 
and relayed to the reviewing pathologist. Recording the site of origin of tissue blocks also facilitates 
retrieval of blocks for further immunohistochemical or molecular analysis, research studies and 
clinical trials. 
 
Extent of sarcomatoid component 
It has been suggested that the proportion of tumour showing sarcomatoid differentiation has 
prognostic significance. There is no recommended or agreed method to calculate the sarcomatoid 
component at present; however, significantly different survival intervals have been demonstrated for 
tumours divided with a cutpoint of <50% and ≥50% sarcomatoid component and these data may be 
included in the report.22,37 
 
Extent of rhabdoid component 
There is currently no firm evidence to demonstrate that the volume of cells showing rhabdoid 
morphology is of prognostic significance.22 
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Extent of necrosis 
The presence of tumour necrosis has been shown to be a prognostic indicator for clear cell RCC but 
has limited or no prognostic implications for papillary RCC. It has also been shown that tumour 
necrosis involving  >10% of the tumour is associated with a less favourable outcome, while for AJCC 
TNM stage 1 and 2 tumours, a cutpoint of 20% of the area of the tumour showing necrosis has been 
suggested to have prognostic significance.52 Although the prognostic significance of the amount of 
necrosis within a tumour is uncertain, it has been recommended that this be recorded as a percentage 
of the total area of tumour sampled,22 determined by gross and microscopic examination. 
 
Lymphovascular invasion 
Lymphovascular invasion includes intratumoral, peritumoral and perirenal space invasion.53 In the 
renal sinus, it may be difficult to distinguish microscopic lymphovascular invasion from involvement 
of thin walled veins lacking smooth muscle. From a practical perspective, the presence of either 
pattern should be considered as renal sinus involvement with a staging category of pT3a. 
 
Microvascular invasion has been shown to correlate with the development of metastases and with 
survival, independent of tumour size, primary tumour category, and grade.54  
 
In both clear cell and papillary RCC, tumour spread is predominantly haematogenous via the sinus 
veins, renal vein and vena cava to the lung. Infiltration of the perirenal fat can result in retroperitoneal 
spread. Lymphatic spread to the nodes of the renal hilum may also occur and is more common in 
papillary RCC than clear cell RCC. 
 
Ancillary findings  
Ancillary studies are being increasingly utilized for subtyping of renal cell neoplasms. Fluorescent in-
situ hybridization (FISH) can be used to confirm a diagnosis of translocation carcinoma (MiT family 
tumour) and has been shown to be of utility in distinguishing oncocytoma from chromophobe RCC.11 
Cytogenetics may be undertaken in some instances; however, this is not usually performed as part of 
the routine assessment of a renal tumour. It is now recognized that immunohistochemical assessment 
of tumours can be diagnostically helpful.55 There are currently no ancillary tests that are accepted as 
having prognostic significance for renal cell neoplasms.55,56 
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Discussion 
 
In 2014, the ICCR made the decision to develop cancer datasets in synchrony with the release of the 
fourth edition of the WHO Classification of Tumours Bluebooks.  The WHO Classification of 
Tumours of the Urinary System and Male Genital Organs was published in 2016 and following this a 
suite of 12 datasets for genitourinary cancer was planned.  With the publication of the eighth edition 
of AJCC TNM Staging Classification towards the end of 2016, the ICCR delayed publication of the 
genitourinary tumour datasets in order to ensure that the final published versions were current with the 
latest staging requirements.  
 
The initial framework of these ICCR datasets was expanded in 2016, with the introduction of a Series 
Champion role.  This role was introduced to provide advice and support to the Chairs of the DACs 
within a specific anatomical series to ensure harmonization across the datasets under development.  
As this role was identified after the commencement of work on the genitourinary tumour datasets, the 
ICCR representative for the genitourinary suite was also appointed Series Champion.  In the 
development of subsequent series of datasets these roles have been separated.  
 
This dataset was developed for excision specimens of the kidney specifically for the reporting of 
invasive carcinoma of renal tubular origin.  A second dataset has been developed for renal biopsies for 
tumour and this is not discussed here.  
 
The dataset incorporates contemporary tumour classification and staging systems and consists of 13 
required elements and 9 recommended elements. In addition two multipart elements i.e. lymph node 
status and extent of invasion, include both required and recommended components.  
 
Considerable advances have been made in our understanding relating to the diagnosis and 
classification of the various morphotypes of RCC and this has informed the development of a variety 
of adjuvant therapies of utility in the treatment of patients with advanced disease. In addition to this 
detailed studies on prognostic parameters for these tumours have led to the development of validated 
grading and staging systems. Despite this several areas of contention remain. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
One of the most challenging issues associated with the classification and prognostic assessment of 
RCC is the ever-increasing list of morphotypes of renal cell neoplasia. The current WHO 
classification recognizes 14 varieties of RCC and in the intervening four years since the publication of 
the fourth edition of the WHO Bluebook,11 four additional morphotypes have been characterized to 
the extent that are likely to included in the next formal classification of renal cell neoplasia (thyroid-
like follicular RCC, multiple oncocytoma-like tumours associated with oncocytosis, biphasic alveolar 
squamoid RCC and eosinophilic solid and cystic RCC).26-28 While it is clear that each form of RCC is 
a unique morphotype there are limited data relating to the clinical behaviour of some of the tumour 
types. It is recognized that TNM staging and WHO/ISUP grading does provide useful prognostic 
information regarding outcome assessment for clear cell and papillary RCC. The significance of these 
parameters is less certain or indeed unknown for several of the more recently described RCC 
morphotypes, due to the limited number of cases with follow-up that have been reported. In view of 
this there is an urgent need for international collaborative studies to fully characterize many of the 
recently described types of RCC.  
 
The prognostic significance of TNM staging of RCC has been validated in multiple studies since the 
release of the first UICC TNM classification in 1978.57 While the  recently published eighth edition of 
the TNM classification from both the UICC and AJCC has incorporated recommendations arising 
from recent studies and contemporary practise, inconsistencies between these two classifications have 
been noted58 and as a consequence the AJCC version2 has been preferred and adopted by the ICCR.  
 
An important outstanding issue relating to staging of RCC concerns the potential overlapping features 
of pT2 and pT3a staging categories. pT2 tumours are defined on the basis of primary tumour size 
(>7cm), while pT3a requires infiltration into the renal vein/ segmental branches, pelvicalyceal system 
or into the renal sinus.12 There is some evidence to indicate that up to 97% of tumours >7cm  diameter 
show renal sinus invasion16 and, as such, tumour size could be considered a surrogate marker of this. 
Detailed studies are required to independently determine the relationship between tumour size and 
renal sinus invasion and that, if appropriate, the defining features of pT2 and pT3a staging categories 
be adjusted accordingly.  
 
The presence of tumour within lymph nodes is the sole definition of N category status in the AJCC 
TNM classification. In earlier versions of the classification quantitation of positive nodes was 
required to determine whether node positive tumours should be categorized as N1 (metastasis in a 
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single regional lymph node) or N2 (metastases in more than one regional lymph node), and this 
impacted upon stage grouping. An early study appeared to validate this sub-division of N positive 
tumours, as it was found that the N category was significantly associated with outcome.
18
 Closer 
scrutiny of the Kaplan-Meier curve in that study shows similar survival for N1 and N2 cases and it is 
apparent that the significant result reported simply reflects the difference between node positive and 
node negative cases. The lack of prognostic significance of cases divided according to the number of 
nodes containing metastatic tumour has been confirmed in a subsequent study.59  Of interest; however, 
this study did show that extra-nodal extension of tumour is of prognostic significance, although this 
has yet to be incorporated into TNM staging. 
 
Grading of RCC has been recognized as an important prognostic parameter since the time of 
Skinner’s landmark studies.57 More recently, refinement of grading criteria  has led to the 
development of  validated grading classifications for clear cell and papillary RCC.22 As noted above, 
grading is one of the parameters that requires validation for many of the recently described 
morphotypes of RCC.  
 
Tumour necrosis is recognized as an important prognostic indicator, especially for clear cell RCC, 
although there is currently some confusion relating its classification and reporting. It is apparent that 
two separate processes may lead to the development of necrosis in clear cell RCC.60-63 Classical 
coagulative necrosis, usually from vascular occlusion with subsequent infarction is usually visible 
macroscopically and may be extensive. A separate form of tumour necrosis, which is rather 
confusingly designated microscopic coagulative necrosis (MCN) appears to develop via a different 
pathogenic mechanism. Despite the terminology, MCN may be macroscopic and does not have the 
typical appearance of coagulative necrosis; however, it is the presence of this type of necrosis that 
appears to have importance as a prognostic indicator. The presence or absence, as well as the 
percentage of tumour showing MCN has been correlated with surrogate prognostic markers and 
patient outcome.60,62,64 It is unfortunately evident that several studies have confused the two types of 
necrosis  and the current recommendations of both the ISUP and the WHO are that both types of 
necrosis should be recorded, which serves to confound prognostic assessment.  Separate studies 
relating to tumour outcome have shown the MCN provides survival information additional to tumour 
grading and for this reason it has been suggested that MCN status should be incorporated into the 
WHO/ISUP grading classification for clear cell RCC.60 
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The presence of sarcomatoid and/or rhabdoid differentiation is incorporated into tumour grading 
criteria for both clear cell and papillary RCC.22 The presence of these morphologies also appears to be 
associated with a similar poor prognosis for other RCC morphotypes.
11
 At present the prognostic 
predictive value resulting from quantitation of the percentage of sarcomatoid differentiation within a 
tumour is uncertain. Some studies have indicated the presence/absence alone is of prognostic 
significance, while others have shown that there is an association between the percentage of tumour 
showing sarcomatoid morphology and decreased survival.34,35,58 Similarly it has been suggested that 
the percentage of high grade (grade 4) tumour present may influence outcome, although this remains 
to be formally validated.65 
 
All ICCR datasets are freely available for worldwide use at the following website: http://www.iccr-
cancer.org/datasets.  
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Figure legends      
 
Figure 1  
Renal malignancy constrained by the renal capsule (arrow), yet no fibrous capsule impedes its growth 
into the vascular tissue of the renal sinus (curved arrows).  
From Bonsib et al.46 The American Journal of Surgical Pathology. © 2000 Wolters Kluwer Health.  
 
Figure 2. T3a 
Invasion into perirenal and/or renal sinus fat but not beyond Gerota’s fascia.  
From the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for 
this material is the AJCC Cancer Staging Atlas 2nd edition (2010) published by Springer Science and 
Business Media LLC, www.springerlink.com. 
 
Figure 3.  
T4 Invasion beyond Gerota’s fascia.  
From the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for 
this material is the AJCC Cancer Staging Atlas 2nd edition (2010) published by Springer Science and 
Business Media LLC, www.springerlink.com. 
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Figure 4:  
T4 Direct extension of tumour into ipsilateral adrenal gland. 
From the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for 
this material is the AJCC Cancer Staging Atlas 2nd edition (2010) published by Springer Science and 
Business Media LLC, www.springerlink.com. 
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